idiopathic generalised epilepsy
Neurology · 2008–2021
4decisions
3medicines
2carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| lacosamide Treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older as add-on therapy in patients… | Mar 2021 | Recommended with restriction | input received |
| perampanel Idiopathic Generalised Epilepsy with Primary Generalised Tonic-Clonic seizures in patients aged 12 years or older, to be used as an additional therapeutic… | Jul 2017 | Recommended | none received |
| perampanel Treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy as adjunctive therapy in combination with two or more… | Jul 2016 | Not recommended | input received |
| levetiracetam Extension of listing to include treatment of primary generalised tonic clonic seizures (PGTCS) and generalised myoclonic seizures as add-on therapy in patients… | Nov 2008 | Recommended with restriction | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.